Epidemiology and management of penicillin-resistant pneumococci

Current Opinion in Infectious Diseases

Volumn 9, Issue 6, 1996, Pages 372-379

  Baquero, Fernando ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PENICILLIN G;

EVOLUTION; HUMAN; INFECTION CONTROL; MINIMUM INHIBITORY CONCENTRATION; PENICILLIN RESISTANCE; REVIEW; RISK ASSESSMENT; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 0030462055     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199612000-00003     Document Type: Review

References (106)

1. McGowan JE Jr, Metchock BG: Penicillin-resistant pneumococci: an emerging threat to successful therapy. J Hosp Infect 1995, 30 (suppl):472-482.
2. Lonks JR, Medeiros AA: The growing threat of antibiotic-resistant Streptococcus pneumoniae. Med Clin North Am 1995, 79:523-535.
3. Anonymous. Defining the public health impact of drug-resistant Streptococcus pneumoniae: report of a working group. MMWR Morb Mortal Wkly Rep 1996, 16(RR1 suppl):1-20.
4. Poole MD: Otitis media complications and treatment failures: implications of pneumococcal resistance. Pediatr Infect Dis J 1995, 14(suppl 4):S23-S26.
5. Krisher K: Antibiotic-resistance in Streptococcus pneumoniae. In Antimicrobial resistance: a crisis in health care. Edited by Jungkind DL, Mortensen J, Fraimow H, Calandra GB. New York: Plenum Press; 1995:123-140.
6. Baquero F: Pneumococcal resistance to beta-lactam antibiotics: a global geographic overview. Microb Drug Resist 1995, 2:115-120.
7. Doern GV, Brueggemann A, Preston Holley HP, Rauch AM: Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 and 1995: results of a 30 center national surveillance study. Antimicrob Agents Chemother 1996, 40:1208-1213.
8. Marchese A, Debbia EA, Arvigo A, Pesce A, Schito GC: Susceptibility of Streptococcus pneumoniae strains isolated in Italy to penicillin and ten other antibiotics. J Antimicrob Chemother 1995, 36:833-837.
9. Kam KM, Luey KY, Fung SM, Yiu PP, Harden TJ, Cheung MM: Emergence of multiple-antibiotic-resistant Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1995, 39:2667-2670.
10. Kihlstrom E, Normann B: Occurrence of pneumococci with resistance or decreased susceptibility to penicillin in southeast Sweden. Scand J Infect Dis 1995, 27:489-494.
11. Wust J, Huf E, Kayser FH: Antimicrobial susceptibilities and serotypes of invasive Streptococcus pneumoniae strains in Switzerland. J Clin Microbiol 1995, 33:3159-3163.
12. Doern GV: Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995, 99(suppl) 3S-7S.
13. Collignon PJ, Bell JM: Drug-resistant Streptococcus pneumoniae: the beginning of the end for many antibiotics? Australian Group on Antimicrobial Resistance (AGAR). Med J Aust 1996, 164:64-67.
14. Duchin JS, Breiman RF, Diamond A, Lipman HB, Block SL, Hedrick JA, Finger R, Elliott JA: High prevalence of multidrug-resistant Streptococcus pneumoniae among children in a rural Kentucky community. Pediatr Infect Dis J 1995, 14:745-750.
15. Reichler MR, Rakovsky J, Slacikova M, Hlavacova B, Krajcikova L, Tarina P, Sobotova A, Facklam RR, Breiman RF: Spread of multidrug-resistant Streptococcus pneumoniae among hospitalized children in Slovakia. J Infect Dis 1996, 173:374-379.
16. Bedos JP, Chevret S, Chastang C, Geslin P, Régnier B, and the French Cooperative Pneumococcus Study Group: Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: findings of a French survey. Clin Infect Dis 1996, 22:63-72. A nationwide study based on microbiological and clinical data that may serve as a modei of epidemiological analysis to define local recommendations to limit the spread of pneumococcal resistance.
17. Baquero F: Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study. J Antimicrob Chemother 1996, 38(suppl A):117-132.
18. Paganin F, Chanez P, Brousse C, Lilienthal F, Darbas H, Jonquet O, Godard P, Michel FB: Community acquired pneumonias in the region of Montpellier. Increase of pneumococci with reduced sensitivity to penicillins [in French]. Presse Med 1995, 24:1341-1344.
19. Chong Y, Lee K, Kwon OH, Henrichsen J: Capsular types and antimicrobial resistance of Streptococcus pneumoniae isolated in Korea. Eur J Clin Microbiol Infect Dis 1995, 14:528-531.
20. Hammond ML, Norriss MS: Antibiotic resistance among respiratory pathogens in preschool children. Med J Aust 1995, 163:239-242.
21. Reichmann P, Varon E, Gunther E, Reinert RR, Luttiken R, Marton A, Geslin P, Wagner J, Hakenbeck R: Penicillin-resistant Streptococcus pneumoniae in Germany: genetic relationship to clones from other European countries. J Med Microbiol 1995, 43:377-385.
22. Cullmann W: Comparative evaluation of orally active antibiotics against community acquired pathogens: a multicenter study in five Mediterranean countries. J Chemother 1995, 7:21-25.
23. Hofmann J, Cetron MS, Farley MM, Baughman WS, Facklam RR, Elliott JA, Deaver KA, Breiman RF: The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995, 333:481-486. How to conduct a laboratory-based surveillance programme for drug resistant pneumococci in your town? Take this model from Atlanta.
24. Verhaegen J, Glupczynski Y, Verbist L, Blogie M, Verbiest N, Vandeven J, Yourassowsky E: Capsular types and antibiotic susceptibility of pneumococci isolated from patients in Belgium with serious infections, 1980-1993. Clin Infect Dis 1995, 20:1339-1345.
25. Nissinen A, Leinonen M, Huovinen P, Herva E, Katila ML, Kontiainen S, Liimatainen O, Oinonen S, Takala AK, Makela PH: Antimicrobial resistance of Streptococcus pneumoniae in Finland, 1987-1990. Clin Infect Dis 1995, 20:1275-1280.
26. Magnus T, Andersen BM: Serotypes and resistance patterns of Streptococcus pneumoniae causing systemic disease in northern Norway. Eur J Clin Microbiol Infect Dis 1995, 14:229-234.
27. Lee HJ, Park JY, Jang SH, Kim JH, Kim EC, Choi KW: High incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumoniae from a university hospital in Korea. Clin Infect Dis 1995, 20:826-835.
28. Evans TG, Kamara A, Minnick K, Blevins D, Sosnowski K: Pneumococcal resistance in southwest Virginia. Antimicrob Agents Chemother 1995, 39:985-986.
29. Reichler MR, Rakovsky J, Sobotova A, Slacikova M, Hlavacova B, Hill B, Krajcikova L, Tarina P, Facklam RR, Breiman RF: Multiple antimicrobial resistance of pneumococci in children with otitis media, bacteremia, and meningitis in Slovakia. J Infect Dis 1995, 171:1491-1496.
30. Yigla M, Finkelstein R, Hashman N, Green P, Cohn L, Merzbach D: Epidemiology and clinical spectrum of pneumococcal infections: an Israeli viewpoint. J Hosp Infect 1995, 29:57-64.
31. Aszkenasy OM, George RC, Begg NT: Pneumococcal bacteraemia and meningitis in England and Wales 1982 to 1992. Commun Dis Rep CDR Rev 1995, 5:R45-R50.
32. Anonymous: Emergence of penicillin-resistant Streptococcus pneumoniae in Southern Ontario, Canada, 1993-1994. MMWR Morb Mortal Wkly Rep 1995, 44:207-209.
33. Pikis A, Akram S, Donkersloot JA, Campos JM, Rodriguez WJ: Penicillin-resistant pneumococci from pediatric patients in the Washington DC area. Arch Pediatr Adolesc Med 1995, 149:30-35.
34. Kristinsson KG: Epidemiology of penicillin resistant pneumococci in Iceland. Microb Drug Resist 1995, 2:121-126.
35. Marton A: Epidemiology of resistant pneumococci in Hungary. Microb Drug Resist 1995, 2:127-130.
36. Baquero F, Loza E, Negri C, Tubau F, Alonso T, Liñares J: Penicillin resistance in S. pneumoniae and in-vitro activity of selected oral antibiotics in Europe. Infect Med 1993, 10(suppl D):25-32.
37. Gratten M, Torzillo P, Morey F, Dixon J, Erlich J, Hagger J, Henrichsen J: Distribution of capsular types and antibiotic susceptibility of invasive Streptococcus pneumoniae isolated from aborigines in Central Australia. J Clin Microbiol 1996, 34:338-341.
38. Tomasz A, Muñoz R: Beta-lactam resistance in Gram positive bacterial pathogens of the upper respiratory tract: a brief overview of mechanisms. 1995. Microb Drug Resist 2:103-110. A short, easy-to-read and enlighted summary on the origin and evolution of the genes involved in streptococcal resistance to beta-lactam agents.
39. Coffey T, Dowson CG, Daniels M, Spratt BG: Genetics and molecular biology of beta-lactam-resistant pneumococci. Microb Drug Resist 1995, 1:29-34.
40. Alcaide F, Liñares J, Pallares R, Carratala J, Benitez MA, Gudiol F, Martún R: In-vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother 1995, 39:2243-2247.
41. Baquero F, Martínez-Beltrán J, Loza E: A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe. J Antimicrob Chemother 1991, 28(suppl C):31-38.
42. Severin A, VazPato MV, Figueiredo AM, Tomasz A: Drastic changes in the peptidoglycan composition of penicillin resistant laboratory mutants of Streptococcus pneumoniae. FEMS Microbiol Lett 1995, 130:31-35.
43. Severin A, Figueiredo AM, Tomasz A: Separation of abnormal cell wall composition from penicillin resistance through genetic transformation of Streptococcus pneumoniae. J Bacteriol 1996, 178:1788-1792.
44. Severin A, Tomasz A: Naturally occurring peptidoglycan variants of Streptococcus pneumoniae. J Bacteriol 1996, 178:168-174.
45. Grabe T, Hakenbeck R: Penicillin-binding protein 2b and 2x of Streptococcus pneumoniae: a primary resistance determinant for different classes of beta-lactam antibiotics. Antimicrob Agents Chemother 1996, 40:829-834.
46. Boken DJ, Chartrand SA, Goering RV, Kruger R, Harrison CJ: Colonization with penicillin-resistant Streptococcus pneumoniae in a childcare center. Pediatr Infect Dis J 1995, 14:879-884.
47. Barnes DM, Whittier S, Gilligan PH, Soares S, Tomasz A, Henderson FW: Transmission of multidrug-resistant serotype 23F Streptococcus pneumoniae in group day care: evidence suggesting capsular transformation of the resistant strain in vivo. J Infect Dis 1995, 171:890-896.
48. Coffey TJ, Daniels M, McDougal LK, Dowson CG, Tenover FC, Spratt BG: Genetic analysis of clinical isolates of Streptococcus pneumoniae with high-level resistance to expanded-spectrum cephalosporins. Antimicrob Agents Chemother 1995, 39:1306-1313.
49. Bouza E, Muñoz P: Penicillin-resistant pneumococci in adult disease with special reference to AIDS patients. Microbial Drug Resist 1995, 1:9-28.
50. McDougal LK, Rasheed JK, Biddle JW, Tenover FC: Identification of multiple clones of extended spectrum cephalosporin resistant Streptococcus pneumoniae isolates in the United States. Antimicrob Agents Chemother 1995, 39:2282-2288.
51. Lefevre JC, Bertrand MA, Faucon G: Molecular analysis by pulsed-field gel electrophoresis of penicillin-resistant Streptococcus pneumoniae from Toulouse, France. Eur J Clin Microbiol Infect Dis 1995, 14:491-497.
52. Gasc AM, Geslin P, Sicard AM: Relatedness of penicillin-resistant Streptococcus pneumoniae serogroup 9 strains from France and Spain. Microbiology 1995, 141:623-627.
53. Barcus VA, Ghanekar K, Yeo M, Coffey TJ, Dowson CG: Genetics of high level penicillin resistance in clinical isolates of Streptococcus pneumoniae FEMS Microbiol Lett 1995, 126:299-303.
54. Smith AM, Klugman KP: Alterations in penicillin-binding protein 2B from penicillin-resistant wild-type strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1995, 39:859-867.
55. Yamane A, Nakano H, Asahi Y, Ubukata U, Komo M: Directly repeated insertion of 9-nucleotide sequence detected in penicillin binding protein 2B gene of penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1996, 40:1257-1259.
56. Negri MC, Morosini MI, Loza E, Baquero F: In-vitro selective concentrations of beta-lactams for penicillin-resistant Streptococcus pneumoniae populations. Antimicrob Agents Chemother 1994, 38:122-125.
57. Jernigan DB, Cetron MS, Breiman RF: Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP). A strategy from the DRSP Working Group. JAMA 1996, 275:206-209.
58. Baquero F and the Task Force of the General Direction for Health Planning of the Spanish Ministry of Health: Antibiotic resistance in Spain: what can be done?. Clin Infect Dis 1996, 23:(in press). Spain is a country with very high rates of pneumococcal resistance. This paper summarizes a document from a Task Force of the Spanish health authorities, to be distributed among practitioners, pharmacists, veterinarians, administrators and the pharmaceutical industry. It is good example of a national approach to fight the problem of antibiotic resistance.
59. Plouffe JF, Breiman RF, Facklam RR: Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group. JAMA 1996, 275:194-198.
60. Hoiby N: Epidemiologic aspects on antibiotic resistance. Microbial Drug Resistance 1995, 1:137-142.
61. Carsenti-Etesse H, Durant J, DeSalvador F, Bensoussan M, Bensoussan F, Pradier C, Thabaut A, Dellamonica P: In-vitro development of resistance to betalactam antibiotics in Streptococcus pneumoniae. J Antimicrob Chemother 1995, 36:417-423.
62. Pankuch GA, Visalli MA, Jacobs MR, Appelbaum PC: Activities of oral and parenteral agents against penicillin-susceptible and resistant pneumococci. Antimicrob Agents Chemother 1995, 39:1499-1504.
63. Fitoussi F, Doit C, Sandin A, Pechinot A, Kazmierczack A, Geslin P, Bingen E: Killing activity of cefpirome against penicillin-resistant Streptococcus pneumoniae isolates from patients with meningitis in a pharmacodynamic model simulating the cerebrospinal fluid concentration profile. Antimicrob Agents Chemother 1995, 39:2560-2563.
64. Block SL, Harrison CJ, Hedrick JA, Tyler RD, Smith RA, Keegan E, Chartrand SA: Penicillin-resistant Streptococcus pneumoniae in acute otitis media: risk factors, susceptibility patterns and antimicrobial management. Pediatr Infect Dis J 1995, 14:751-759.
65. Farr BM, Johnston BL, Cobb DK, Fisch MJ, Germanson TP, Adal KA, Anglim AM: Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med 1995, 155:2336-2340.
66. Zenni MK, Cheatham SH, Thompson JM, Reed GW, Batson AB, Palmer PS, Holland KL, Edwards KM: Streptococcus pneumoniae colonization in the young child: association with otitis media and resistance to penicillin. J Pediatr 1995, 127:533-537.
67. Friedland IR: Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J 1995, 14:885-890.
68. Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, Martin R, Gudiol F: Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995, 333:474-480.
69. Knudsen JD, Frimodt-Moller N, Espersen F: Experimental Streptococcus pneumoniae infection in mice for studying correlation of in-vitro and in-vivo activities of penicillin against pneumococci with various susceptibilities to penicillin. Antimicrob Agents Chemother 1995, 39:1253-1258. The correlation of the in-vitro activity, the in-vivo effect and the pharmacokinetics of penicillin is studied. The authors used 10 pneumococcal strains with penicillin MICs ranging from 0.016 to 8 μg/ml. This type of study is pivotal for the design of new strategies of antibiotic use.
70. Gehanno P, Lenoir G, Berche P: In-vivo correlates for Streptococcus pneumoniae penicillin resistance in acute otitis media. Antimicrob Agents Chemother 1995, 39:271-272.
71. Guibert M, Chahime H, Petit J, Odievre M, Labrune P: Failure of cefotaxime treatment in two children with meningitis caused by highly penicillin-resistant Streptococcus pneumoniae. Acta Paediatr 1995, 84:831-833.
72. Klugman KP, Friedland IR, Bradley JS: Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother 1995, 39:1988-1992.
73. Cormican MG, Erwin ME, Jones RN: Bactericidal activity of cefotaxime, desacetyl-cefotaxime, rifampin, and various combinations tested at cerebrospinal fluid levels against penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1995, 22:119-123.
74. Tubau F, Cabello C, Liñares J: Lack of correlation between in-vitro and in-vivo studies of associations of rifampin plus vancomycin or beta-lactam antibiotics against Streptococcus pneumoniae. Antimicrob Agents Chemother 1996, 40:1573-1574.
75. Redondo E, Clynes N, Hoffman J, Cetron MS, Breiman RF, Farley MM, Pallares R, Liñares J, Gudiol F: Drug-resistant Streptococcus pneumoniae. N Engl J Med 1996, 334:53-55.
76. Chavanet P, Beloeil H, Pechinot A, Duigou F, Buisson JC, Duong M, Neuwirth C, Kazmierczak A, Portier H: In-vivo activity and pharmacodynamics of cefotaxime or ceftriaxone in combination with fosfomycin in fibrin clots infected with highly penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1995, 39:1736-1743.
77. Nairn K, Shepherd GL, Edwards JR: Efficacy of meropenem in experimental meningitis. J Antimicrob Chemother 1995, 36(suppl A):73-84.
78. Rylander M, Rollof J, Jacobsson K, Norrby SR: Comparative antibacterial activity of L695,256, a carbapenem active against methicillin-resistant staphylococci. Antimicrob Agents Chemother 1995, 39:1178-1181.
79. Cormican MG, Jones RN: Evaluation of the in-vitro activity of furopenem (SY5555 or SUN5555) against respiratory tract pathogens and beta-lactamase producing bacteria. J Antimicrob Chemother 1995, 35:535-539.
80. Moreno S, Garcia-Leoni ME, Cercenado E, Diaz MD, Bernaldo de Quiros JC, Bouza E: Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. Clin Infect Dis 1995, 20:1195-1200.
81. Poulsen RL, Knudsen JD, Petersen MB, Fuursted K, Espersen F, Frimodt-Moller N: In-vitro activity of six macrolides, clindamycin and tetracycline on Streptococcus pneumoniae with different penicillin susceptibilities. APMIS 1996, 104:227-233.
82. Burucoa C, Pasdeloup T, Chapon C, Fauchere JL, Robert R: Failure of pristinamycin treatment in a case of pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 1995, 14:341-342.
83. Barry AL, Fuchs PC: In-vitro activities of a streptogramin (RP 59500), three macrolides, and an azalide against four respiratory tract pathogens. Antimicrob Agents Chemother 1995, 39:238-240.
84. Johnson CC, Slavoski L, Schwartz M, May P, Pitsakis PG, Shur AL, Levison ME: In-vitro activity of RP 59500 (quinupristin/ dalfopristin) against antibiotic resistant strains of Streptococcus pneumoniae and enterococci. Diagn Microbiol Infect Dis 1995, 21:169-173.
85. Pankuch GA, Lichtenberger C, Jacobs MR, Appelbaum PC: Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies. Antimicrob Agents Chemother 1996, 40:1653-1656.
86. Rajagopalan-Levasseur P, Vallee E, Agouridas C, Chantot JF, Pocidalo JJ: RU-004: activity against erythromycin-resistant pneumococci and Haemophilus influenzae in murine pneumonia models. abstract F173. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, ASM, Washington.
87. Weiss WJ, Jacobus NV, Petersen PJ, Testa RT: Susceptibility of enterococci, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae to the glycyl-cyclines. J Antimicrob Chemother 1995, 36:225-230.
88. Finch RG: The role of new quinolones in the treatment of respiratory tract infections. Drugs 1995, 49(suppl 2):144-151.
89. Eliopoulos GM: In-vitro activity of fluoroquinolones against Gram-positive bacteria. Drugs 1995, 49(suppl 2):48-57.
90. Baquero F, Cantón C: In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract infections. J Antimicrob Chemother 1996, 37(suppl A):1-18.
91. Klugman K, Wasas A: In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and resistant Streptococcus pneumoniae. J Antimicrob Chemother 1995, 36:873-874.
92. Kitzis MD, Goldstein FW, Ishida N, Acar JF: SYN-987, SYN-1193, and SYN-1253, new quinolones highly active against grampositive cocci. J Antimicrob Chemother 1995, 36:209-213.
93. Viselli MA, Jacobs MR, Applebaum PC: MIC and time-kill studies of DU-68590, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1996, 40:362-366.
94. Paris MM, Hickey SM, Trujillo M, Shelton S, McCracken GH Jr: Evaluation of CP99,219, a new fluoroquinolone, for treatment of experimental penicillin and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1995, 39:1243-1246.
95. Pankuch GA, Jacobs MR, Appelbaum PC: Activity of CP-99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother 1995, 35:230-232.
96. Spangler SK, Jacobs MR, Applebaum PC: Activities of RPR-106972 (a new oral streptogramin), cefditoren (a new cephalosporin), two new oxazolidinones (U-100592 and U-100766) and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneucococci. Antimicrob Agents Chemother 1996, 40:481-484.
97. Mason ED, Lamberth LB, Kaplan SL: In-vitro activity of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1996, 40:1039-1040.
98. Biedebach DJ, Sutton LD, Jones RN: Antimicrobial activity of CS-940, a new trifluorinated quinolone. 1995. Antimicrob Agents Chemother 1995, 39:2328-2330.
99. Pankuch GA, Jacobs MR, Appelbaum PC: Activity of DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and OPC-17116 against 112 penicillin susceptible and resistant pneumococci. Drugs 1995, 49(suppl 2):235-237.
100. Morrissey I, Smith JT: The new 4-quinolones DU-6859a and DV-7751a show enhanced activity against Streptococcus pneumoniae. Drugs 1995, 49(suppl 2):228-229.
101. Munford RS, Murphy TV: Antimicrobial resistance in Streptococcus pneumoniae: can immunization prevent its spread? J Invest Med 1994, 42:613-621.
102. Stephenson J: Conjugate vaccines hold hope for countering resistant pneumococcus. JAMA 1995, 274:1327-1328.
103. Klein DL: Pneumococcal conjugate vaccines: review and update. Microb Drug Resist 1995, 1:49-57.
104. McCracken GH Jr: Emergence of resistant Streptococcus pneumoniae: a problem in pediatrics. Pediatr Infect Dis J 1995, 14:424-428.
105. Klugman KP, Friedland IR: Antibiotic-resistant pneumococci in pediatric disease. Microb Drug Resist 1995, 1:5-8.
106. Rijkers GT, Sanders EAM, Breukels MA, Zegers BJM: Responsiveness of infants to capsular polysaccharides: implications for vaccine development. Rev Med Microbiol 1996, 7:3-12.